Maravai Lifesciences Holdings Inc (MRVI)vsRegeneron Pharmaceuticals Inc (REGN)
MRVI
Maravai Lifesciences Holdings Inc
$3.11
+0.97%
HEALTHCARE · Cap: $1.13B
REGN
Regeneron Pharmaceuticals Inc
$749.47
+1.05%
HEALTHCARE · Cap: $78.41B
Smart Verdict
WallStSmart Research — data-driven comparison
Regeneron Pharmaceuticals Inc generates 7622% more annual revenue ($14.34B vs $185.74M). REGN leads profitability with a 31.4% profit margin vs -70.4%. REGN earns a higher WallStSmart Score of 58/100 (C).
MRVI
Avoid24
out of 100
Grade: F
REGN
Buy58
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for MRVI.
Margin of Safety
-165.8%
Fair Value
$281.93
Current Price
$749.47
$467.54 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Reasonable price relative to book value
Keeps 31 of every $100 in revenue as profit
Safe zone — low bankruptcy risk
Large-cap with strong market position
Attractively priced relative to earnings
Reasonable price relative to book value
Strong operational efficiency at 23.1%
Areas to Watch
Smaller company, higher risk/reward
Weak financial health signals
ROE of -48.6% — below average capital efficiency
Revenue declined 11.8%
Expensive relative to growth rate
2.5% revenue growth
Weak financial health signals
Earnings declined 2.6%
Comparative Analysis Report
WallStSmart ResearchBull Case : MRVI
The strongest argument for MRVI centers on Debt/Equity, Price/Book.
Bull Case : REGN
The strongest argument for REGN centers on Profit Margin, Altman Z-Score, Market Cap. Profitability is solid with margins at 31.4% and operating margin at 23.1%.
Bear Case : MRVI
The primary concerns for MRVI are Market Cap, Piotroski F-Score, Return on Equity.
Bear Case : REGN
The primary concerns for REGN are PEG Ratio, Revenue Growth, Piotroski F-Score.
Key Dynamics to Monitor
MRVI profiles as a turnaround stock while REGN is a value play — different risk/reward profiles.
REGN carries more volatility with a beta of 0.40 — expect wider price swings.
REGN is growing revenue faster at 2.5% — sustainability is the question.
REGN generates stronger free cash flow (922M), providing more financial flexibility.
Bottom Line
REGN scores higher overall (58/100 vs 24/100), backed by strong 31.4% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Maravai Lifesciences Holdings Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Maravai LifeSciences Holdings, Inc., a life sciences company, offers products to enable the development of drug therapies, diagnostics, novel vaccines, and to support human disease research in the United States and internationally. The company is headquartered in San Diego, California.
Visit Website →Regeneron Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company then branched out into the study of both cytokine and tyrosine kinase receptors.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?